Literature DB >> 33407499

DLG1-AS1 is activated by MYC and drives the proliferation and migration of hepatocellular carcinoma cells through miR-497-5p/SSRP1 axis.

Jie Min1, Dayong Jin2, Feng Zhang1, Yanxia Kang1, Yuhong Qi3, Pang Du4.   

Abstract

BACKGROUND: Long non-coding RNAs (lncRNAs) have been reported to be biological regulators in hepatocellular carcinoma (HCC). DLG1 antisense RNA 1 (DLG1-AS1) has been found to be up-regulated in cervical cancer. However, its function and underlying mechanism in HCC remains unknown.
METHODS: DLG1-AS1 expression was assessed in HCC cells and normal cell by RT-qPCR. Luciferase reporter assay, RNA pull down assay and RIP assay were used to demonstrate the interaction between DLG1-AS1 and miR-497-5p.
RESULTS: DLG1-AS1 was highly expressed in HCC cells. Silencing of DLG1-AS1 led to the inhibition of HCC cell growth and migration. Besides, MYC induced the transcriptional activation of DLG1-AS1. MYC could facilitate HCC cellular processes by up-regulating DLG1-AS1. MiR-497-5p could interact with DLG1-AS1 in HCC cells. Down-regulation of miR-497-5p could reverse the impacts of DLG1-AS1 silencing on HCC cells. SSRP1 expression could be positively regulated by DLG1-AS1 but was negatively regulated by miR-497-5p. Knockdown of DLG1-AS1 suppressed tumor growth in nude mice.
CONCLUSIONS: DLG1-AS1 is activated by MYC and functions as an oncogene in HCC via miR-497-5p/SSRP1 axis.

Entities:  

Keywords:  DLG1-AS1; Hepatocellular carcinoma; MYC; SSRP1; miR-497-5p

Year:  2021        PMID: 33407499     DOI: 10.1186/s12935-020-01667-0

Source DB:  PubMed          Journal:  Cancer Cell Int        ISSN: 1475-2867            Impact factor:   5.722


  36 in total

Review 1.  Long noncoding RNAs in normal and pathological pluripotency.

Authors:  Sophia J Häfner; Thomas G Talvard; Anders H Lund
Journal:  Semin Cell Dev Biol       Date:  2016-07-18       Impact factor: 7.727

Review 2.  Long Noncoding RNAs in Cardiovascular Pathology, Diagnosis, and Therapy.

Authors:  Christian Bär; Shambhabi Chatterjee; Thomas Thum
Journal:  Circulation       Date:  2016-11-08       Impact factor: 29.690

3.  dot-app: a Graphviz-Cytoscape conversion plug-in.

Authors:  Braxton Fitts; Ziran Zhang; Massoud Maher; Barry Demchak
Journal:  F1000Res       Date:  2016-10-20

4.  LncRNA GHET1 predicts poor prognosis in hepatocellular carcinoma and promotes cell proliferation by silencing KLF2.

Authors:  Li Jin; Yangke He; Shijia Tang; Shan Huang
Journal:  J Cell Physiol       Date:  2017-12-26       Impact factor: 6.384

Review 5.  The diagnosis and treatment of hepatocellular carcinoma.

Authors:  Justin Hartke; Matthew Johnson; Marwan Ghabril
Journal:  Semin Diagn Pathol       Date:  2016-12-20       Impact factor: 3.464

6.  LncRNA DLG1-AS1 Promotes Cancer Cell Proliferation in Triple Negative Breast Cancer by Downregulating miR-203.

Authors:  Shuyan Li
Journal:  J Breast Cancer       Date:  2020-08-25       Impact factor: 3.588

Review 7.  Targeted Therapy for Hepatocellular Carcinoma.

Authors:  Nitin Ohri; Andreas Kaubisch; Madhur Garg; Chandan Guha
Journal:  Semin Radiat Oncol       Date:  2016-06-15       Impact factor: 5.934

Review 8.  Privileged portal metastasis of hepatocellular carcinoma in light of the coevolution of a visceral portal system and liver in the chordate lineage: a search for therapeutic targets.

Authors:  Vladimir M Subbotin
Journal:  Drug Discov Today       Date:  2018-01-09       Impact factor: 7.851

9.  Long non-coding RNA HOXA11-AS promotes the proliferation HCC cells by epigenetically silencing DUSP5.

Authors:  Bin Liu; Jing Li; Xiaoling Liu; Min Zheng; Ye Yang; Qian Lyu; Li Jin
Journal:  Oncotarget       Date:  2017-11-27

10.  SP1-induced lncRNA AGAP2-AS1 expression promotes chemoresistance of breast cancer by epigenetic regulation of MyD88.

Authors:  Huaying Dong; Wei Wang; Shaowei Mo; Ru Chen; Kejian Zou; Jing Han; Fan Zhang; Jianguo Hu
Journal:  J Exp Clin Cancer Res       Date:  2018-08-29
View more
  1 in total

Review 1.  The Current Status of SSRP1 in Cancer: Tribulation and Road Ahead.

Authors:  Shengnan Jia; Baofeng Guo; Lihui Wang; Liping Peng; Ling Zhang
Journal:  J Healthc Eng       Date:  2022-04-13       Impact factor: 3.822

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.